Zhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline
- Extending the Cooperation in Pulmonary Arterial Hypertension
News provided by
Share this article
Share this article
SHANGHAI, Mar. 17, 2021 /PRNewswire/ Zhongchao Inc. (NASDAQ: ZCMD) ( Zhongchao or the Company ), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced the renewal of its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline (China) Investment Limited to continue the medical education program Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals ( PAH Project ) in 2021.
The PAH Project aims to promote the implementation of the multidisciplinary treatment model of pulmonary hypertension and improve doctors ability to solve clinical problems. In 2020, more than 200 experts in pulmonary hyp
Zhonachao Reports Renewal of Partnership with China Association of Health Promotion and Education and GlaxoSmithKline | Zhonachao Reports Renewal of Partnership with China Association of Health Promotion and Education and GlaxoSmithKlineFinancial Buzz financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Zhongchao Inc. Shares Rise After Renewing its Contract with China Association of Health Promotion and Education and GlaxoSmithKline”
Zhongchao Inc.
(NASDAQ: ZCMD) shot up just over 87% in premarket trading after the company renewed its partnership with the China Association for Health Promotion and Education and GlaxoSmithKline Investment Limited.
The partnership seeks to continue the medical education program “Pulmonary Arterial Hypertension Online Course – Connections with Famous Hospitals”, which aims to promote the implementation of the multidisciplinary treatment model of pulmonary hypertension and improve doctors’ ability to solve clinical problems.